Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

25 Oct 2016 17:43

RNS Number : 4431N
GW Pharmaceuticals PLC
25 October 2016
 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Mr Julian Gangolli

2.

Reason for the notification

a.

Position/status

Director/President, US

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Exercise of share options to acquire ordinary shares.

 

c.

Price(s) and volume(s)

 

Price(s)

 0.1p

Volume(s)

10,608

 

Ordinary shares acquired pursuant to option exercise

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

 London

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each and American Depositary Shares

 Ordinary Shares: ISIN: GB0030544687

American Depositary shares: ISIN: US36197T1034

b.

Nature of the transaction

Conversion of Ordinary shares into American Depositary Shares (12 to 1 conversion ratio)

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

301

 

ADS's issued upon conversion of 3,612 Ordinary shares

d.

Aggregated information

·Aggregated volume

·Price

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

 

 

American Depositary Shares

ISIN: 36197T1034

b.

Nature of the transaction

Sale of American Depositary shares

c.

Price(s) and volume(s)

 

Price(s)

 $120.75

Volume(s)

301

 

ADS's sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary Share and Restricted American Depositary Shares

Ordinary Shares: ISIN: GB0030544687

Restricted American Depositary shares: ISIN: US36197T1372

b.

Nature of the transaction

Conversion of Ordinary Shares into Restricted American Depositary shares (12 to 1 Conversion ratio)

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

583

Restricted ADSs issued upon conversion of 6,996 Ordinary Shares

d.

Aggregated information

·Aggregated volume

·Price

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Mr Christopher Tovey

2.

Reason for the notification

a.

Position/status

Director/Chief Operations Officer

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Exercise of share options to acquire ordinary shares.

c.

Price(s) and volume(s)

 

Price(s)

 0.1p

Volume(s)

266,557

 

Ordinary shares acquired pursuant to option exercise

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

 London

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each and American Depositary Shares

 Ordinary Shares: ISIN: GB0030544687

American Depositary shares: ISIN: US36197T1034

b.

Nature of the transaction

Conversion of Ordinary shares into American Depositary Shares (12 to 1 conversion ratio)

c.

Price(s) and volume(s)

 

Price(s)

 -

Volume(s)

22,213

ADS's issued upon conversion of 266,556 Ordinary shares

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

New York

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

American Depositary Shares

ISIN: US36197T1034

b.

Nature of the transaction

Sale of American Depositary shares

c.

Price(s) and volume(s)

 

Price(s)

 $120.36

Volume(s)

22,213

 

ADS's sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

Nasdaq, New York 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Dr Geoffrey Guy

2.

Reason for the notification

a.

Position/status

Director/Chairman of the Board

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary Shares

c.

Price(s) and volume(s)

 

Price(s)

 £8.43p

Volume(s)

206,100

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

21 October 2016

f.

Place of the transaction

 AIM, London

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

 Ordinary Shares: ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary shares

c.

Price(s) and volume(s)

 

Price(s)

 £8.24

Volume(s)

68,900

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

24 October 2016

f.

Place of the transaction

AIM, London

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

0.1 Pence Ordinary Shares

ISIN:GB0030544687

b.

Nature of the transaction

Sale of Ordinary shares

c.

Price(s) and volume(s)

 

Price(s)

 £8.09

Volume(s)

125,000

 

Ordinary Shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

25 October 2016

f.

Place of the transaction

AIM, London

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Dr Stephen Wright

2.

Reason for the notification

a.

Position/status

Director/Chief Medical Officer

b.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

GW Pharmaceuticals PLC

b.

LEI

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type of instrument

Identification code

Ordinary shares of 0.1p each

ISIN: GB0030544687

b.

Nature of the transaction

Sale of Ordinary Shares by the wife of Dr Stephen Wright

c.

Price(s) and volume(s)

 

Price(s)

 £8.10p

Volume(s)

1,556

 

Ordinary shares sold

d.

Aggregated information

·Aggregated volume

·Price

 

 

n/a

e.

Date of the transaction

25 October 2016

f.

Place of the transaction

 AIM, London

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFSRIILEFIR
Date   Source Headline
8th Sep 20152:37 pmRNSBlock Listing Application
17th Aug 20159:14 amRNSBlocklisting Interim Review
6th Aug 201512:28 pmRNSThird Quarter 2015 Financial Results
6th Aug 201511:45 amRNSFDA Fast Track and EMA Orphan Designations for CBD
23rd Jul 201512:00 pmRNSNotice of Results
16th Jul 20154:15 pmRNSAppointment of Director
16th Jul 201510:40 amRNSHolding(s) in Company
9th Jul 20154:57 pmRNSHolding(s) in Company
9th Jul 20154:24 pmRNSHolding(s) in Company
7th Jul 20153:23 pmRNSHolding(s) in Company
30th Jun 20157:00 amRNSDirector/PDMR Shareholding
24th Jun 20155:56 pmRNSDirector/PDMR Shareholding
12th Jun 20155:39 pmRNSDirector/PDMR Shareholding
11th Jun 201512:00 pmRNSSecond Ph3 Pivotal Study of Epidiolex in LGS
1st Jun 201510:19 amRNSBlock Listing Application
1st Jun 20157:54 amRNSHolding(s) in Company
1st Jun 20157:53 amRNSHolding(s) in Company
29th May 201511:13 amRNSHolding(s) in Company
19th May 201512:00 pmRNSAppoints US Executive; Relocates CEO to US
15th May 20155:43 pmRNSPurchase of Additional American Depositary Shares
11th May 20153:00 pmRNSPresenting at BAML 2015 Healthcare Conference
11th May 201512:00 pmRNSHalf Yearly Report
11th May 201512:00 pmRNSInitiates Ph3 Pivotal Study of Epidiolex in LGS
11th May 201511:45 amRNSHolding(s) in Company
11th May 201511:45 amRNSHolding(s) in Company
8th May 20154:22 pmRNSHolding(s) in Company
6th May 201512:00 pmRNSNotice of Results
6th May 201512:00 pmRNSInitiates Phase 2 Trial of CBDV in Epilepsy
6th May 20157:01 amRNSClosing of U.S. Public Offering of ADSs
1st May 20153:28 pmRNSHolding(s) in Company
1st May 20157:30 amRNSHolding(s) in Company
29th Apr 20157:00 amRNSPricing of U.S. Public Offering of ADSs
28th Apr 20157:00 amRNSProposed Public Offering of ADSs
27th Apr 201512:00 pmRNSUS Patent Allowance for Use of Cannabidivarin
24th Apr 201512:00 pmRNSOrphan Drug Designation for CBD in NHIE
23rd Apr 20157:00 amRNSNew Physician Reports of Epidiolex Treatment
21st Apr 201512:00 pmRNSStarts 2nd Ph 3 Epidiolex Trial in Dravet Syndrome
14th Apr 20157:00 amRNSNew Epidiolex Data Released by AAN
1st Apr 20152:03 pmRNSHolding(s) in Company
31st Mar 201512:00 pmRNSStarts Ph 3 Trial for Epidiolex in Dravet Syndrome
17th Mar 20155:18 pmRNSHolding(s) in Company
17th Mar 20155:15 pmRNSHolding(s) in Company
25th Feb 201512:00 pmRNSPresenting at Upcoming Investor Conferences
17th Feb 20153:25 pmRNSBlocklisting Interim Review
16th Feb 20153:52 pmRNSHolding(s) in Company
16th Feb 20153:48 pmRNSHolding(s) in Company
9th Feb 20155:31 pmRNSDirector/PDMR Shareholding
5th Feb 20152:25 pmRNSResult of AGM
5th Feb 201512:00 pmRNSPresents at Leerink Global Healthcare Conference
4th Feb 201512:01 pmRNS1st Quarter Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.